CXCL10 and head and neck squamous cell carcinoma: Thus, as an alternative to combinations of EGFR/ERBB inhibitors with existing anti-PD1/PD-L1 agents, combining EGFR/ERBB inhibitors with novel agents that either enhance production of T cell attractants (like CXCL10) or inhibit production of chemokines/cytokines that recruit pro-tumorigenic immune cells like MDSCs may represent a next generation of therapeutic strategies in HNSCC.